1.1 Carfilzomib in combination with dexamethasone is recommended as an option for treating multiple myeloma in adults, only if:
they have had only 1 previous therapy, which did not include bortezomib and
the company provides carfilzomib with the discount agreed in the patient access scheme.
1.2 These recommendations are not intended to affect treatment with carfilzomib that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.